Sarcos Robotics
CPS 31Sarcos develops robotic exoskeletons and AI-powered robotics software that enable superhuman physical task performance and autonomous operations.
Sarcos Robotics (now Palladyne AI/PDYN) has executed a dramatic pivot from hardware exoskeletons to software-first embodied AI, but remains a high-risk turnaround with unproven recurring software revenue, heavy reliance on recently acquired defense manufacturing for near-term revenue, and a stock that has declined ~90% from its 2021 ATH. The 2026 revenue guide of $24-27M is credibly underpinned by backlog and acquisitions, but sustainable value creation depends on demonstrating a repeatable software licensing model (Palladyne IQ/Pilot) that has yet to materialize at scale, while integration risk across three late-2025 acquisitions and elevated short interest (~21.5%) create significant execution and financing uncertainty.
Defense pipeline is expanding with named contracts: USAF $13.8M success-based learning contract, USAF swarming/satellite integration award, propulsion subsystem contract with a major U.S. defense prime (~$1M), and Portal Space Systems spacecraft contract via GuideTech
Cash position of ~$47M at YE2025 provides 12+ months of runway, and 2026 revenue guidance of $24-27M represents a 336-440% YoY step-up with >$13M contracted backlog expected to convert within 12 months
IntelliSwarm first flight on Banshee loitering munition achieved after only a 3-week integration, demonstrating rapid software-to-hardware deployment velocity that could differentiate in defense procurement cycles
Late-2025 acquisitions (GuideTech, Warnke, MKR) provide vertically integrated U.S.-based precision manufacturing, avionics IP (BRAIN X2), and entry into sticky, long-lifecycle defense programs (F-35 components, missile systems)
Edge-first, closed-loop autonomy architecture (low data, low power) aligns with IFR-identified industry trends and DoD requirements for resilient, non-cloud-dependent autonomous systems in contested environments
Dramatic OpEx reduction (-73% YoY in Q2 2024) and organizational restructuring demonstrate management's willingness to make hard pivots and impose cost discipline
Legacy Guardian XO exoskeleton — once the flagship product — is now discontinued, and the company has yet to prove it can commercialize its software replacement (Palladyne IQ) at scale, with sales cycles of 12-18+ months and trade-policy headwinds elongating integrator decision-making
2026 revenue is predominantly hardware/manufacturing from acquisitions, not software licensing — creating a margin profile inconsistent with the 'software-first' narrative and risking valuation compression versus pure software peers
Share count has risen ~36.7% YoY to ~44.7M shares, with additional dilution risk from S-3 shelf registration, up to $25M in earnout obligations (payable in stock), and ~5.36M performance RSUs; short interest at ~21.5% signals significant bearish conviction
Integration risk across three simultaneous acquisitions (GuideTech, Warnke, MKR) is non-trivial — cultural alignment, ERP/QA harmonization, and program management must all execute in parallel during 2026
Stock has declined from $66.72 ATH (Sept 2021) to $6.72 (Feb 2026), a ~90% destruction of value, with extreme volatility and event-driven trading patterns that suggest speculative rather than fundamental investor base
No demonstrated recurring software ARR or maintenance revenue stream as of early 2026; the entire software thesis remains aspirational until IQ/Pilot generate measurable, repeatable licensing income
Backlog conversion failure: >$13M backlog must convert in 2026 to hit guidance; defense program delays, testing failures, or customer changes could derail the revenue step-up
Software revenue remains aspirational: Palladyne IQ has been in trials since mid-2024 with no disclosed recurring licensing revenue; 12-18+ month sales cycles and integrator caution could push meaningful software ARR to 2027 or beyond
Dilution risk: S-3 shelf registration, $25M earnout (payable in stock), and performance RSUs could significantly increase share count; elevated short interest (~21.5%) amplifies downside on any equity issuance
Acquisition integration complexity: Three simultaneous integrations across manufacturing, avionics, and software teams with different cultures, systems, and quality standards create operational risk
Defense funding dependency: Revenue concentration in government contracts exposes the company to budget cycles, continuing resolutions, and program cancellation risk
Technology validation gap: Closed-loop autonomy in unstructured environments requires robust V&V practices that are still evolving industry-wide; any safety incident could severely damage adoption prospects
FY2025 audited results and FY2026 quarterly earnings demonstrating backlog conversion and margin profile from acquired businesses (expected H1 2026)
First disclosed commercial Palladyne IQ licensing/subscription revenue from industrial customers, validating the software-first pivot thesis
Additional defense production orders for Banshee/SwarmStrike or expansion of USAF swarming programs beyond development phase into production contracts
Successful integration milestones across GuideTech, Warnke, and MKR — evidenced by on-time delivery metrics and stable/improving gross margins
Resolution of trade-policy uncertainty that could accelerate industrial integrator purchasing decisions and shorten IQ sales cycles